Eli Lilly and Company $LLY Shares Acquired by Cooper Financial Group

Cooper Financial Group increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,776 shares of the company’s stock after buying an additional 502 shares during the quarter. Cooper Financial Group’s holdings in Eli Lilly and Company were worth $6,683,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp grew its holdings in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Healthcare was one of the market’s few strong sectors, with Eli Lilly among the leaders. The relative strength likely reflects continued investor preference for defensive healthcare companies and Lilly’s strong growth profile. Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
• Positive Sentiment: Analysts and commentators highlighted growth opportunities beyond Mounjaro and Zepbound, including oncology, immunology, neuroscience, insulin and other pipeline programs. This supports the view that Lilly’s long-term outlook is not dependent on a single obesity-drug franchise. Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
• Positive Sentiment: Recent data for Lilly’s oral GLP-1 candidate Foundayo reportedly showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could broaden access and add another major growth driver, though the analysis still requires further validation. Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis
• Positive Sentiment: Retatrutide, Lilly’s next-generation triple-hormone obesity candidate, was identified as a potentially underappreciated catalyst. Reported trial weight loss has exceeded Zepbound’s results, and a regulatory filing is expected in early 2027. Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
• Neutral Sentiment: Investment commentary remains divided: Lilly’s rapid revenue and earnings growth support premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution errors. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: The World Health Organization’s new childhood-obesity guidelines could increase scrutiny of obesity-drug use in younger patients and create additional regulatory or adoption hurdles for Lilly and Novo Nordisk. Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines

Eli Lilly and Company Trading Up 2.5%

Eli Lilly and Company stock traded up $29.46 during midday trading on Wednesday, reaching $1,186.95. 2,300,611 shares of the stock traded hands, compared to its average volume of 2,974,313. The company has a 50-day simple moving average of $1,173.51 and a two-hundred day simple moving average of $1,094.59. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The firm has a market cap of $1.12 trillion, a PE ratio of 39.83, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on LLY shares. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada boosted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Jefferies Financial Group increased their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,312.36.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.